导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.26% | 1419/4773 |
| 近一周 | -2.20% | 1477/5462 |
| 近一月 | -1.28% | 898/5421 |
| 近一季 | -1.37% | 982/5209 |
| 近半年 | -6.75% | 3132/4920 |
| 近一年 | 9.89% | 1052/4366 |
| 近两年 | 48.95% | 1501/2954 |
| 近三年 | 42.10% | 671/2253 |
| 成立以来 | 187.24% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
4.69% 482/4961 |
-5.96% 3646/5312 |
- - |
- - |
| 2025 | 18.01% 2343/4813 |
-1.93% 2819/3635 |
0.27% 2717/4076 |
14.71% 2879/4524 |
4.62% 508/4813 |
| 2024 | 17.84% 650/3463 |
7.91% 213/2808 |
0.97% 517/3014 |
9.82% 2666/3129 |
-1.52% 1737/3463 |
| 2023 | 10.62% 91/2656 |
7.55% 556/2280 |
2.03% 179/2385 |
2.16% 249/2515 |
-1.33% 307/2655 |
| 2022 | -10.54% 208/2207 |
-0.48% 129/1919 |
-1.95% 1763/2016 |
-9.56% 289/2113 |
1.37% 1288/2208 |
| 2021 | 26.68% 95/1822 |
9.05% 56/1255 |
2.95% 985/1330 |
7.74% 173/1466 |
4.73% 318/1822 |
| 2020 | 26.86% 593/1250 |
-5.50% 426/1028 |
11.99% 706/1067 |
16.40% 153/1164 |
2.99% 949/1184 |
| 2019 | 23.59% 625/1092 |
23.95% 536/754 |
-5.40% 467/804 |
-0.27% 588/850 |
5.68% 692/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富国中证价值ETF VS. 长安沪深300非周期A(740101) |